Welcome to my podcast. I am Doctor Warrick Bishop, and I want to help you to live as well as possible for as long as possible. I’m a practising cardiologist, best-selling author, keynote speaker, and the creator of The Healthy Heart Network. I have over 20 years as a specialist cardiologist and a private practice of over 10,000 patients.

Podcast Summary

Introduction

Dr. Warrick Bishop is a practicing cardiologist and author dedicated to improving patient care through health education. In this episode, he discusses non-alcoholic fatty liver disease (NAFLD) and its inflammatory progression to non-alcoholic steatohepatitis (NASH), conditions that are becoming increasingly prevalent as they now surpass alcoholic fatty liver disease as the leading cause of liver fat accumulation.

Key Takeaways:

• NAFLD (non-alcoholic fatty liver disease) is fat accumulation in the liver unrelated to alcohol consumption, while NASH represents the inflammatory stage of this disease that can progress to cirrhosis.

• Morbid obesity is the single biggest driver of NAFLD, and rising obesity rates in communities are directly increasing the incidence of fatty liver disease.

• Insulin resistance, stemming from obesity or type 2 diabetes, causes a shift in free fatty acid release and accumulation within liver cells, distorting liver architecture and function.

• Fructose consumption significantly contributes to fatty liver development; while fruit is healthy, excessive fructose from fruit juice, fruit wraps, and processed foods can overload the liver in people at risk.

• NAFLD often produces no symptoms, but central obesity (fat around the midsection) and abnormal liver enzyme blood tests may indicate fatty liver disease.

• Progressive liver disease can develop serious complications including cirrhosis, liver failure, itching, bleeding problems, jaundice, and ultimately requires transplantation to survive.

• Weight reduction is the most critical intervention; Dr. Bishop recommended bariatric surgery for a patient whose dietary efforts failed, resulting in 35+ kilograms of weight loss and improved liver function.

• Ezetimibe, a cholesterol-lowering medication, has a protective effect on NAFLD through its action on the NCP1L2 receptor and can be used alongside statins.

• Statins are not detrimental to NAFLD progression and may offer slight protective benefits, contrary to previous concerns.

• Awareness and early intervention are essential, as NAFLD is an underrecognized obesity complication that will increasingly impact mortality if left unaddressed.